ストックスクリーナーアプリを入手
0.5658
37.14%
-0.3343
アフターアワーズ：
.58
0.0142
+2.51%
前日終値:
$0.9001
開ける：
$0.65
24時間の取引高:
3.15M
Relative Volume:
33.92
時価総額：
$29.45M
収益：
-
当期純損益:
$-16.26M
株価収益率:
-0.4789
EPS:
-1.1814
ネットキャッシュフロー:
$-13.50M
1週間 パフォーマンス:
-69.42%
1か月 パフォーマンス:
-72.13%
6か月 パフォーマンス:
-82.75%
1年 パフォーマンス:
-85.58%
1日の値動き範囲:
$0.55
$0.65
1週間の範囲:
$0.55
$1.9424
52週間の値動き範囲:
$0.55
$5.275
Intensity Therapeutics Inc Stock (INTS) Company Profile
名前
Intensity Therapeutics Inc
セクター
電話
203-221-7381
住所
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
INTS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
0.5658 | 29.45M | 0 | -16.26M | -13.50M | -1.1814 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Intensity Therapeutics Inc (INTS) 最新ニュース
Analysts Conflicted on These Healthcare Names: Regeneron (REGN), Community Health (CYH) and Integer Holdings (ITGR) - The Globe and Mail
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com
United States shares higher at close of trade; Dow Jones Industrial Average up 0.05% - Investing.com India
Intensity Therapeutics sets terms for $2.35 million offering - Investing.com
Shelton biotech eyes $2.35M public offering to fund research - Hartford Business Journal
Intensity Therapeutics plunges on $2.35M public offering - MSN
Why Intensity Therapeutics (INTS) Stock Is Getting Hammered - Benzinga
Intensity Therapeutics (INTS) Launches Public Offering to Raise $2.35 Million | INTS Stock News - GuruFocus
US Stock Futures Dip As Oil Prices Continue To Slide - Finimize
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering - PR Newswire
Intensity Therapeutics Inc (INTS)’s stock performance: a year in review - uspostnews.com
Intensity Therapeutics Inc’s Bumpy Road: Analyzing the 52-Week Range and Future Prospects - investchronicle.com
INTS stock touches 52-week low at $1.49 amid market challenges - Investing.com Australia
Dow Jumps Over 1,000 Points; Tesla Shares Rise After Q1 Results - Benzinga
Intensity Therapeutics Highlights Cancer Treatment Progress - TipRanks
Is RollsRoyce (RYCEY) Stock Outpacing Its Aerospace Peers This Year? - Yahoo Finance
Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year? - Yahoo Finance
Why ArcelorMittal (MT) is a Top Value Stock for the Long-Term - Yahoo Finance
Tesla Delays Launch of Cheaper, Stripped-Down Version of Model Y in US - Yahoo Finance
The Zacks Analyst Blog Highlights Affirm, StoneCo, ACI Worldwide, Coinbase Global and OppFi - Yahoo Finance
Brokers Suggest Investing in QuickLogic (QUIK): Read This Before Placing a Bet - Yahoo Finance
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement - Quantisnow
Jim Cramer: Cencora (COR) Is a “Must-Own” Drug Middleman – Even If It Should Be Digitized Away - Yahoo Finance
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™ - PR Newswire UK
US Radiotherapy Market worth US$2.49 billion by 2030 with 4.6% CAGR | MarketsandMarkets™. - The Manila Times
Relation of Low-Density Lipoprotein Cholesterol, High-Sensitivity C-Reactive Protein, and Lipoprotein(a) Each to Future Cardiovascular Events and Death After Acute Coronary Syndrome on High-Intensity Statin Therapy: An Analysis of the Placebo Arm of OD - American Heart Association Journals
IntercontinentalExchange price target lowered to $230 from $237 at BofA - Yahoo Finance
Has Cencora, Inc. (COR) Outpaced Other Medical Stocks This Year? - Yahoo Finance
Why Iridium Communications (IRDM) is a Top Value Stock for the Long-Term - Yahoo Finance
Soft Tissue Sarcoma Treatment Market Size in 7MM is expected - openPR.com
Insiders At Cencora Sold US$16m In Stock, Alluding To Potential Weakness - Yahoo Finance
Leading Factor Driving the Burkitt Lymphoma Therapeutics Market in 2025: Impact Of Rising HIV Incidence On ... - WhaTech
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga
Soft Tissue Sarcoma Clinical Pipeline | 70+ Companies Driving Innovation in Treatment - openPR
Benchmark maintains Speculative Buy on Intensity Therapeutics By Investing.com - Investing.com South Africa
Benchmark maintains Speculative Buy on Intensity Therapeutics - Investing.com
Soft Tissue Neoplasms Treatment Market Size in 7MM is expected - openPR
Bristol-Myers Squibb (NYSE:BMY) Gets EC Nod For Breyanzi In NHL Treatment - Yahoo Finance
INTENSITY THERAPEUTICS Earnings Results: $INTS Reports Quarterly Earnings - Nasdaq
Small Number of Acne Products Recalled for Problematic Levels of Benzene - 69News WFMZ-TV
Intensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update - Longview News-Journal
Tempest Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:TPST - Benzinga
Bile Duct Neoplasms Treatment Market Size Report 2032 | Taewoong - openPR.com
Alpheus Medical Publishes Promising Early Clinical Results of Sonodynamic Therapy for the Treatment of Newly Diagnosed Glioblastomas - BioSpace
Equillium (NASDAQ:EQ) Stock Quotes, Forecast and News Summary - Benzinga
Thyroid Cancer Market Size to Reach USD 1,892.4 Million by 2035, Impelled by Advancements in Gene Therapy and Personalized Medicine - BioSpace
Small-Cap Grace Therapeutics Touts Positive Data From Brain Hemorrhage Study - Benzinga
Grafapex Approved for Reduced-Intensity Stem Cell Transplants in AML and MDS Patients - Managed Healthcare Executive
Intensity Infrastucture Partners Launches Open Season for New Natural Gas Transmission Pipeline to Serve the Bakken Region - Yahoo Finance
Intensity Therapeutics Inc (INTS) 財務データ
収益
当期純利益
現金流量
EPS
0.24%
36.06%
大文字化:
|
ボリューム (24 時間):